To discuss treatment decisions in the first-line setting of metastatic renal cell carcinoma (mRCC).

Immune check point inhibitor (ICI) combinations have replaced sunitinib as the standard of care in the first-line treatment of mRCC. check details Dual ICI treatment with nivolumab and ipilimumab was shown to significantly improve overall…[Read more]